Navigation Links
Oncothyreon reports first quarter 2009 financial results
Date:5/14/2009

re> Oncothyreon Inc. Consolidated Statements of Operations and Other Comprehensive Loss Data (in thousands except per share amounts) (unaudited) Three Months Ended March 31 -------------------------- 2009 2008 ------------ ------------ Revenue Contract manufacturing $ - $ 1,718 Licensing revenue from collaborative agreements 4 302 ------------ ------------ 4 2,020 ------------ ------------ Expenses Research and development 680 2,308 Manufacturing - 2,080 General and administrative 1,751 2,703 Depreciation 65 103 Investment and other income, net (20) (60) ------------ ------------ 2,476 7,134 ------------ ------------ Net loss (2,472) (5,114) Other comprehensive loss - (103) ------------ ------------ Comprehensive net loss
'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncothyreon regains compliance with NASDAQ listing requirements
2. Oncothyreon to present at Invest Northwest 2009
3. Oncothyreon reports full year and fourth quarter 2008 financial results
4. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
5. Oncothyreon to present at BIO CEO & Investor Conference 2009
6. Oncothyreon reports third quarter 2008 financial results
7. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
8. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
9. Oncothyreon to present at BIO Investor Forum 2008
10. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
11. Oncothyreon announces prioritization plan for development programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015 /CNW/ - Bioenterprise Corporation is pleased to ... in Charlottetown , PEI.  Bioenterprise has ... Island ADAPT Council for the commercialization of agricultural technologies ... working with PEI ADAPT.  They have been at the ... a decade," explains Dave Smardon , President & ...
(Date:4/16/2015)... SAN DIEGO , April 16, 2015 /PRNewswire/ ... and development of therapeutic antibodies, today announced ... (IL-36R) antibody program into IND-enabling studies. The ... a novel treatment for generalized pustular psoriasis ... high unmet medical need. ANB019 is wholly owned ...
(Date:4/16/2015)... , April 16, 2015  EMD Serono today ... Darmstadt, Germany , appointed ... Head of Global Clinical Development.  Dr. Reicin brings ... experience in Oncology and Immunology. She is an ... served as a Vice President in various capacities ...
(Date:4/16/2015)... Madison, NJ (PRWEB) April 16, 2015 ... recruited Dr. Joseph V. Gulfo to become the ... and Entrepreneurship. Simultaneously, FDU announced the kick-off of ... new program spearheaded by Dr. Gulfo, under the ... Silberman College of Business) and in collaboration with ...
Breaking Biology Technology:Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... June 9 to discuss the prevalence and prevention of NSAID-induced ... - , , BETHESDA, Md. and ... and Horizon Therapeutics, Inc. today launched Connect to Protect ... risks associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs), ...
... week 26 in moderate to severe Crohn,s patients who ... CHICAGO, June 1 New data from the WELCOME ... meeting demonstrate that Cimzia(R) (certolizumab pegol) provides sustained symptom ... patients suffering from moderate to severe Crohn,s disease (CD) ...
... KVISTGAARD, Denmark, June 1 Detailed data from,a ... the,ASCO Annual Meeting in Orlando. The presentation was made by ... and the Dana-Farber Cancer,Institute who is also the principal investigator ... detailed analysis supports the headline data that were reported,in October ...
Cached Biology Technology:AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 2AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 3Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 2Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 3Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 4Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 5Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 6Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 7Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 8Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 9Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 10PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer 2PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer 3
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
(Date:3/12/2015)... -- IriTech, a leading iris based identity management technology ... Design Network, announced today that the Chief Minister ... MK2120U device during a launching event of Andhra Pradesh ... The iris scanner is manufactured by U.S. based ... India through its Indian partner, Biometronic Technology, ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3
... sea areas a serious ecological threat to the ... the environment, e.g. the increase of fish-eating animals ... One of the new guiding principles of political ... "ecosystems approach" should be used instead of traditional ...
... In the work defended at the University of the Basque ... cancer was created in order to reproduce the gene regulation ... as metastasis in the liver of patients. This in vitro ... identification of the origin of the factors regulating this expression, ...
... In the world of commercial materials, lighter and cheaper ... with superior strength and special properties, such as a ... been deformed by a physical or magnetic force. ,A ... has been developed by two research teams headed by ...
Cached Biology News:Fisheries should be regarded as a part of the maritime environment 2It is important to demonstrate the influence of the microenvironment in the process of metastasis 2It is important to demonstrate the influence of the microenvironment in the process of metastasis 3Metal foam has a good memory 2
... cDNA normalization is essential for ... using high-throughput approaches, such as EST ... Most normalization methods are not well ... cDNA. The Evrogen TRIMMER kit, though, ...
... SNP loci identification through targeting resequencing. ... design, intensive assay validation/optimization, high throughput ... or customer-supplied samples and sequence alignment ... for rapid and highly accurate identification ...
... Tissue Extract Protein Array Kit is designed ... extracts. The expression of a protein in ... specific antibody. When the antibody binds the ... sensitive chemiluminescent or fluorescent signal created by ...
... delivers enhanced statistics and statistical interpretation ... improvement managers. As an accepted organizational ... simplifies statistics for novice users and ... experts. It offers a powerful JMP ...
Biology Products: